Trastuzumab rezetecan for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your breast cancer has returned or spread and cannot be removed by surgery.
- You have not had chemotherapy for advanced cancer, but you have tried at least one hormone therapy that no longer works.
- Your cancer has gotten worse on recent treatment, as shown by scans.
- You are able to take care of yourself (ECOG score 0 or 1).
- You agree to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This study tests a new drug called trastuzumab rezetecan for people with advanced solid tumors that show a certain protein (HER2). The drug targets HER2 to help kill cancer cells, and the goal is to see if it is safe and effective.
This trial tests a new sequence of targeted therapies for advanced HER2-positive breast cancer. It aims to see if giving these drugs in a specific order can shrink tumors and delay progression better than current approaches.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
Hear when a new Unresectable Locally Recurrent Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.